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a bs t r ac t
BACKGROUND

Higher serum urate levels are associated with an increased risk of diabetic kidney
disease. Lowering of the serum urate level with allopurinol may slow the decrease
in the glomerular filtration rate (GFR) in persons with type 1 diabetes and earlyto-moderate diabetic kidney disease.
METHODS

In a double-blind trial, we randomly assigned participants with type 1 diabetes, a serum urate level of at least 4.5 mg per deciliter, an estimated GFR of 40.0 to 99.9 ml
per minute per 1.73 m2 of body-surface area, and evidence of diabetic kidney disease
to receive allopurinol or placebo. The primary outcome was the baseline-adjusted
GFR, as measured with iohexol, after 3 years plus a 2-month washout period.
Secondary outcomes included the decrease in the iohexol-based GFR per year and
the urinary albumin excretion rate after washout. Safety was also assessed.
RESULTS

A total of 267 patients were assigned to receive allopurinol and 263 to receive
placebo. The mean age was 51.1 years, the mean duration of diabetes 34.6 years,
and the mean glycated hemoglobin level 8.2%. The mean baseline iohexol-based
GFR was 68.7 ml per minute per 1.73 m2 in the allopurinol group and 67.3 ml per
minute per 1.73 m2 in the placebo group. During the intervention period, the mean
serum urate level decreased from 6.1 to 3.9 mg per deciliter with allopurinol and
remained at 6.1 mg per deciliter with placebo. After washout, the between-group
difference in the mean iohexol-based GFR was 0.001 ml per minute per 1.73 m2 (95%
confidence interval [CI], −1.9 to 1.9; P = 0.99). The mean decrease in the iohexolbased GFR was −3.0 ml per minute per 1.73 m2 per year with allopurinol and −2.5 ml
per minute per 1.73 m2 per year with placebo (between-group difference, −0.6 ml per
minute per 1.73 m2 per year; 95% CI, −1.5 to 0.4). The mean urinary albumin excretion rate after washout was 40% (95% CI, 0 to 80) higher with allopurinol than with
placebo. The frequency of serious adverse events was similar in the two groups.
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CONCLUSIONS

We found no evidence of clinically meaningful benefits of serum urate reduction
with allopurinol on kidney outcomes among patients with type 1 diabetes and
early-to-moderate diabetic kidney disease. (Funded by the National Institute of
Diabetes and Digestive and Kidney Diseases and others; PERL ClinicalTrials.gov
number, NCT02017171.)
n engl j med 382;26

nejm.org

June 25, 2020

2493

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on September 23, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

T

he estimated lifetime risk of diabetic kidney disease among patients with
type 1 diabetes is as high as 60%.1 Intensive glucose control was widely implemented to
reduce the incidence of microalbuminuria after
the Diabetes Control and Complications Trial,2
but longer follow-up suggested that intensified
glucose control delays but does not eliminate the
risk of progression of diabetic kidney disease to
end-stage kidney disease.3 In fact, the annual
incidence of end-stage kidney disease among
persons with type 1 diabetes in the United States
has been increasing, albeit in a delayed fashion,
as compared with earlier cohorts.4 Although bloodpressure control5,6 and, more specifically, renin–
angiotensin system inhibition7-9 slow the progression of relatively advanced diabetic kidney
disease, evidence of preservation of the glomerular filtration rate (GFR) by these interventions at
earlier stages is limited.10-13 Thus, new treatments,
especially for early diabetic kidney disease, are
needed.
Serum urate is a potential target, on the basis
of evidence from animal models and observational studies involving humans.14 Higher levels
of serum urate, even within the normal range,
predicted albuminuria14-16 and early decline in
the GFR as well as a higher rate of cardiovascular events and higher mortality in cohorts of
patients with type 1 diabetes.14,17,18 Moreover,
reduction in the serum urate level slowed the
decline in the GFR in two small clinical trials
involving participants with moderate chronic
kidney disease, approximately 25% of whom had
diabetes.19-21 In the Preventing Early Renal Loss
in Diabetes (PERL) trial, we tested whether reduction of the serum urate level with allopurinol
therapy could slow the decline in GFR in persons
with type 1 diabetes, early-to-moderate diabetic
kidney disease, and a serum urate level of at
least 4.5 mg per deciliter (270 μmol per liter).22
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States, Canada, and Denmark. The first author
served as the sponsor-investigator (according to
the Food and Drug Administration, a person
who initiates and conducts an investigation and
under whose immediate direction the investigational drug is administered or dispensed). Members of the steering committee designed the
trial, supervised its conduct, and were responsible for reporting the results. Analyses were performed by the trial statistical team, which comprised three authors. Five of the authors wrote
the initial draft of the manuscript, and all the
authors contributed to revisions. The decision to
submit the manuscript for publication was made
jointly by all the authors, who also vouch for the
accuracy and completeness of the data and for
the fidelity of the trial to the protocol (available
with the full text of this article at NEJM.org). The
iohexol that was used for assessing the iohexolbased GFR was donated by GE Healthcare,
which had no role in the trial design or conduct
or in the data collection or analysis but which
reviewed the manuscript to ensure that no confidential information was disclosed.
Patients

Included in the trial were patients with type 1
diabetes; an estimated GFR of 40.0 to 99.9 ml
per minute per 1.73 m2 of body-surface area;
evidence of diabetic kidney disease, defined as a
history of or the presence of albuminuria (urinary albumin excretion rate, 20 to 3333 μg per
minute) or evidence of a decline in the GFR of at
least 3 ml per minute per 1.73 m2 per year in the
previous 3 to 5 years; and a serum urate level of
at least 4.5 mg per deciliter (corresponding to
the median value in a population of patients
with similar characteristics17).22 Inclusion and exclusion criteria are summarized in Table S1 in the
Supplementary Appendix, available at NEJM.org.
Trial Procedures

Me thods
Trial Design and Oversight

The rationale and design of this double-blind,
multicenter, randomized, placebo-controlled clinical trial of allopurinol have been published previously.22 The trial, which was supported by the
National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) and JDRF (previously
known as the Juvenile Diabetes Research Foundation), was conducted at 16 sites in the United
2494
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Eligible participants entered a 9-week run-in phase
during which, if indicated, renin–angiotensin
system inhibitors were introduced or adjusted
(to be at least equivalent to 10 mg of ramipril or
300 mg of irbesartan) and the blood pressure
was targeted to no higher than 140/90 mm Hg.
Participants were then randomly assigned to receive either oral placebo or allopurinol (at a dose
of 100 mg per day for 4 weeks, with the dose
adjusted thereafter to 400 mg per day if the estimated GFR was ≥50 ml per minute per 1.73 m2,
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to 300 mg per day if the estimated GFR was 25 to
49 ml per minute per 1.73 m2, or to 200 mg per
day if the estimated GFR was 15 to 24 ml per
minute per 1.73 m2). Randomization was stratified according to site, serum urate level (≤6.0 vs.
>6.0 mg per deciliter [≤360 vs. >360 μmol per
liter]), and glycated hemoglobin level (≤7.8% vs.
>7.8%), with the use of permuted blocks of two
or four. The intervention period lasted 3 years
plus a 2-month washout period.
Trial visits (which occurred every 3 to 4 months)
included measurements of blood pressure, serum
creatinine, and glycated hemoglobin as well as
safety evaluations. The GFR was measured by
plasma disappearance of iohexol (iohexol-based
GFR)23 immediately before randomization, midway through the trial (at 80 weeks), at the end of
the intervention period (at 156 weeks), and after
the washout period (at 164 weeks).
The trial was conducted in accordance with
the principles of the Declaration of Helsinki, the
international ethical guidelines of the Council
for International Organizations of Medical Sciences, and the Good Clinical Practice guidelines
of the International Council for Harmonisation.
The protocol was reviewed by all local institutional review boards and the NIDDK-appointed
data and safety monitoring board. All the participants provided written informed consent.
Outcomes

The primary outcome was the iohexol-based GFR
after 3 years plus the 2-month washout period,
with adjustment for the baseline iohexol-based
GFR. This outcome was selected because studies
have indicated that the measured GFR was more
sensitive for the detection of GFR change than
the GFR estimating equations24,25 and because
our goal was to ascertain effects that are independent of the possible transient renal hemodynamic effects of allopurinol.26 Secondary outcomes were the following: the baseline-adjusted
iohexol-based GFR after the 3-year intervention
period; the iohexol-based GFR time trajectory as
estimated from measurements conducted at baseline, at mid-trial, at the end of the intervention, and
at the end of the washout period; the baselineadjusted serum creatinine–based estimated GFR
(assessed with the Chronic Kidney Disease Epidemiology Collaboration equation27) at 4 months;
the estimated GFR time trajectory with the use
of serum creatinine levels obtained at intervals
of 3 to 4 months; doubling of the serum creatin engl j med 382;26

nine level or progression to end-stage kidney
disease in a time-to-event analysis; the baselineadjusted urinary albumin excretion rate after
washout; the baseline-adjusted urinary albumin
excretion rate after 3 years; and fatal or nonfatal
cardiovascular events (defined as death from
cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, coronary-artery bypass
grafting, or percutaneous coronary intervention)
in a time-to-event analysis.
Statistical Analysis

On the basis of data from the Joslin Kidney
Study,17 we estimated that 180 participants per
group would provide the trial with 80% power to
detect a prespecified effect of 3 ml per minute
per 1.73 m2 on the primary outcome, assuming
a two-sided type I error of 5% and a standard
deviation of the residual error of 10.1 ml per
minute per 1.73 m2. To account for a trial discontinuation rate of up to 5% per year from
withdrawal, death, or progression to end-stage
kidney disease and for a discontinuation rate of
allopurinol or placebo of up to 2% per year
among participants completing the trial, we aimed
to randomly assign 240 patients per group to
maintain adequate power. When this number
was reached, it was decided, in agreement with
the data and safety monitoring board and the
NIDDK, to randomly assign participants who
were still in the run-in period to the trial groups,
which brought the total to 530 participants.
The primary analysis was conducted in the
intention-to-treat population, which included all
the patients who had undergone randomization.
A secondary analysis was conducted in the perprotocol population, which included participants
who had a mean exposure to allopurinol or placebo of at least 80% over the 3-year trial period
and who had no major protocol deviations. Multiple imputation methods were applied28 with
the use of fully conditional specification29 to
account for missing values for continuous outcomes, baseline covariates, and postrandomization variables of interest (see the Supplementary
Statistical Methods section in the Supplementary
Appendix).
The effect of allopurinol on the primary outcome was evaluated with the use of a linear
model for correlated errors with a general or
unstructured covariance matrix with the following covariates: stratification variables, baseline
value of the dependent variable, kidney pheno-

nejm.org

June 25, 2020

2495

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on September 23, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

Table 1. Characteristics of the Trial Participants at Baseline.*
Characteristic

Placebo
(N = 263)

Allopurinol
(N = 267)

Total
(N = 530)

Age — yr

51.8±10.6

50.4±11.2

51.1±10.9

Male sex — no. (%)

168 (63.9)

183 (68.5)

351 (66.2)

White

216 (82.1)

230 (86.1)

446 (84.2)

Black

30 (11.4)

28 (10.5)

58 (10.9)

Other

17 (6.5)

9 (3.4)

26 (4.9)

Race — no. (%)†

Diabetes duration — yr

35.3±12.5

33.8±12.2

34.6±12.3

Body-mass index

29.5±5.9

29.5±6.1

29.5±6.0

Glycated hemoglobin — %

8.2±1.3

8.2±1.3

8.2±1.3

Serum urate — mg/dl‡

6.1±1.5

6.1±1.5

6.1±1.5

Systolic

126.3±13.6

125.6±14.7

126.0±14.2

Diastolic

71.3±10.0

71.2±10.4

71.2±10.2

Blood pressure — mm Hg‡

Iohexol-based GFR — ml/min/1.73

m2‡

Serum creatinine–based estimated GFR — ml/min/1.73 m2‡
Median urinary albumin excretion rate (IQR) — μg/min§
Use of renin–angiotensin system inhibitor — no. (%)

67.3±16.7

68.7±17.1

68.0±16.9

74.0±19.4

75.4±18.7

74.7±19.1

43.0 (9.0–198.0)

41.1 (7.7–216.0)

41.6 (8.5–207.5)

230 (87.5)

247 (92.5)

477 (90.0)

*	Plus–minus values are means ±SD. Data on body-mass index (the weight in kilograms divided by the square of the height in meters) were
missing for three participants in the placebo group and for two in the allopurinol group, on the glycated hemoglobin level for two in the
allopurinol group, on the iohexol-based glomerular filtration rate (GFR) for one in the placebo group, and on the urinary albumin excretion
rate for two in the placebo group. To convert the values for serum urate to micromoles per liter, multiply by 59.48. IQR denotes interquartile
range.
†	Race was reported by the patient.
‡	Values were obtained at the visit before randomization.
§	The values are based on geometric means of the albumin excretion rates obtained at the two visits before randomization.

type (albuminuric diabetic kidney disease vs.
normoalbuminuria with declining kidney function), and baseline albumin excretion rate (see
the Supplementary Statistical Methods section).
The robustness of the results was assessed by a
tipping-point sensitivity analysis.30 Secondary outcomes were analyzed by means of linear regression (for outcomes at a single time point), a linear
model with correlated errors (for the iohexolbased GFR at the end of the intervention period),
mixed-effects models (for longitudinal measures
of the postrandomization iohexol-based GFR
and estimated GFR), and a proportional-hazards
model (for time-to-event end points). Albumin
excretion rates were log-transformed.
Since there were no interim analyses of the
primary outcome, the nominal alpha level for
the primary outcome was set at 0.05. For secondary outcomes, 95% confidence intervals are
reported, without P values. The confidence intervals are not adjusted for multiplicity and should
2496
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not be used to infer treatment effects. Prespecified subgroup analyses were performed for possible heterogeneity in the effects of allopurinol
treatment on the primary outcome by adding
appropriate interaction terms to the model for
the primary analysis.

R e sult s
Patients

Of 1625 persons screened, 1016 were ineligible,
withdrew, or were lost to follow-up before the
run-in phase, 609 entered the run-in phase, and
530 finished the run-in phase and were randomly assigned to receive either allopurinol (267
patients) or placebo (263 patients) (Fig. S1). The
clinical characteristics of the patients at baseline
were well balanced between the two groups (Table 1 and Table S2). The mean age of the patients
was 51.1 years, and the mean duration of diabetes was 34.6 years. The mean iohexol-based GFR
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A total of 62 participants (23.2%) in the allopurinol group and 46 (17.5%) in the placebo group
did not complete the trial owing to voluntary
withdrawal, loss to follow-up, death, progression
to end-stage kidney disease, or other reasons
(Fig. S1). A total of 10 patients in the allopurinol
group died, as compared with 4 in the placebo
group; 6 and 2 patients, respectively, had progression to end-stage kidney disease. A total of
14 patients (5.2%) in the allopurinol group and
19 (7.2%) in the placebo group completed the
trial but discontinued allopurinol or placebo before 3 years for protocol-mandated reasons (e.g.,
rash) or on their own initiative. Data on the completeness of the iohexol-based GFR measurements obtained during the trial are provided in
the Supplementary Appendix.
The median adherence to the assigned regimen (assessed as the percentage of tablets taken)
was 93.8% (interquartile range, 86.3 to 97.4),
with 85.4% of the participants having at least
80% adherence, and 94.9% of the patients having at least 70% adherence. The serum urate
level, which remained at baseline levels in the
placebo group, decreased progressively in the
allopurinol group from 6.1 mg per deciliter at
baseline to 3.7 mg per deciliter (220 μmol per
liter) at 16 weeks and remained at that level for
the duration of the intervention period (mean,
3.9 mg per deciliter [230 μmol per liter], equivalent to a 36% reduction from the baseline value);
after the washout period, the serum urate level
returned to a near-baseline value (mean, 5.9 mg
per deciliter [350 μmol per liter]) (Fig. 1A). The
values for the glycated hemoglobin level, systolic
and diastolic blood pressure, and body-mass
index remained similar to the baseline values in
the two groups (Fig. S2).

8

Serum Urate (mg/dl)

Trial Follow-up and Adherence

A

Iohexol-Based GFR (ml/min/1.73 m2)

was 68.0 ml per minute per 1.73 m2, and the
mean estimated GFR was 74.7 ml per minute per
1.73 m2. The mean serum urate level was 6.1 mg
per deciliter (360 μmol per liter), and the mean
glycated hemoglobin level was 8.2%. A total of
90.0% of the patients were treated with renin–
angiotensin inhibitors.

Weeks since Randomization

Figure 1. Serum Urate and Iohexol-based Glomerular Filtration Rate (GFR)
Trajectories.
The mean levels of serum urate (Panel A) and the mean iohexol-based GFR
(Panel B) in the two groups are shown at different time points during the
trial. I bars indicate 95% confidence intervals. The mean serum urate val‑
ues are shown for participants with available levels at each time point. The
mean iohexol-based GFR values are shown for the entire intention-to-treat
population, with missing values imputed as described in the Methods sec‑
tion. The intervention period ended at week 156 after randomization, and
the 2-month washout period ended at week 164. To convert the values for
serum urate to micromoles per liter, multiply by 59.48.

Results of Allopurinol Treatment on Primary
and Secondary Outcomes

When values were adjusted for the baseline values,
The iohexol-based GFR in the intention-to-treat the mean iohexol-based GFR at the end of the
population decreased at similar rates in the allo 2-month washout period (the primary outcome)
purinol group and the placebo group (Fig. 1B). was virtually identical in the two groups (61.2 ml
n engl j med 382;26
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Table 2. Effect of Allopurinol on Primary and Secondary Outcomes.*
Placebo
(N = 263)

Allopurinol
(N = 267)

Allopurinol Effect
(95% CI)†

61.2
(58.1 to 64.2)

61.2
(58.1 to 64.2)

0.001
(−1.9 to 1.9)‡

Baseline-adjusted iohexol-based GFR at end of the intervention
period (95% CI) — ml/min/1.73 m2

61.0
(57.9 to 64.0)

61.3
(58.3 to 64.3)

0.3
(−1.7 to 2.3)

Baseline-adjusted estimated GFR at 4 mo after randomization
(95% CI) — ml/min/1.73 m2

70.0
(67.1 to 72.9)

70.3
(67.3 to 73.3)

0.3
(−1.6 to 2.2)

Iohexol-based

−2.5
(−3.1 to −1.8)

−3.0
(−3.7 to −2.3)

−0.6
(−1.5 to 0.4)

Estimated

−2.1
(−2.6 to −1.6)

−2.4
(−2.9 to −1.8)

−0.3
(−1.0 to 0.5)

At end of the washout period

31.7
(19.5 to 51.6)

42.9
(24.7 to 74.4)

1.4
(1.0 to 1.8)

At end of the intervention period

37.4
(25.3 to 55.5)

47.9
(32.5 to 70.6)

1.3
(1.0 to 1.6)

Serum creatinine doubling or progression to end-stage kidney
disease — no. (%)§

11 (4.2)

13 (4.9)

1.2
(0.5 to 2.9)

Fatal or nonfatal cardiovascular event — no. (%)

9 (3.4)

15 (5.6)

1.9
(0.8 to 4.5)

Outcome
Primary outcome
Baseline-adjusted iohexol-based GFR at end of the 2-mo washout
period (95% CI) — ml/min/1.73 m2
Secondary outcomes

Slope of GFR (95% CI) — ml/min/1.73 m2/yr

Urinary albumin excretion rate (95% CI) — μg/min

*	Data for continuous outcomes are adjusted means, except for outcomes involving the urinary albumin excretion rate, for which they are
adjusted geometric means.
†	For GFR outcomes, the allopurinol effect is the estimated difference between the allopurinol group and the placebo group; for urinary al‑
bumin excretion rate outcomes, it is the ratio between the allopurinol group and the placebo group; and for the time-to-event analyses of
serum creatinine doubling or progression to end-stage kidney disease and of fatal or nonfatal cardiovascular events, it is the hazard ratio
for the events with allopurinol as compared with placebo.
‡	P = 0.99.
§	Two patients in the placebo group and six in the allopurinol group had progression to end-stage kidney disease.

per minute per 1.73 m2 in each group; betweengroup difference, 0.001 ml per minute per 1.73 m2;
95% confidence interval [CI], −1.9 to 1.9) (Table 2). These results were supported by a tippingpoint sensitivity analysis, which indicated that a
very large deviation, on the order of 9 ml per
minute per 1.73 m2, from the imputed values in
the allopurinol group at the visit at which the
primary outcome was assessed would have been
necessary to overturn these neutral findings (see
the Supplementary Appendix).
There was no evidence of a difference between
the groups in a secondary analysis conducted in
the per-protocol population (Table S3). In this
population, the baseline-adjusted iohexol-based
GFR at the end of the trial was 63.5 ml per minute
per 1.73 m2 in the allopurinol group and 62.0 ml
per minute per 1.73 m2 in the placebo group
2498
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(between-group difference, 1.5 ml per minute
per 1.73 m2; 95% CI, −0.7 to 3.8). Prespecified
subgroup analyses of the primary outcome in
the intention-to-treat population did not reveal
significant heterogeneity in response to allopurinol (Fig. 2).
We did not find evidence of clinically meaningful effects with regard to the secondary outcomes of the baseline-adjusted iohexol-based
GFR at the end of the intervention period or at
4 months, the slope of the iohexol-based GFR,
and the slope of the estimated GFR (Table 2).
The urinary albumin excretion rate was 40% (95%
CI, 0 to 80) higher at the end of the washout
period and 30% (95% CI, 0 to 60) higher at the
end of the intervention period in the allopurinol
group than in the placebo group. Results in the
time-to-event analyses of serum creatinine dou-
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Placebo

Allopurinol

263

267

106
157

116
151

95
168

84
183

30
233

28
239

146
117

151
116

120
143

119
146

94
168

86
181

206
46

212
47

92
171

97
170

Between-Group Difference in GFR (95% CI)
ml/min/1.73 m2

no. of patients

Subgroup
All patients
Age
≤50 yr
>50 yr
Sex
Female
Male
Race
Black
Nonblack
Serum urate
≤6 mg/dl
>6 mg/dl
Glycated hemoglobin
≤7.8%
>7.8%
Iohexol-based GFR
≤60 ml/min/1.73 m2
>60 ml/min/1.73 m2
Type of diabetic kidney disease
Albuminuric diabetic kidney disease
Normoalbuminuria with declining kidney function
Urinary albumin excretion rate
≤20 µg/min
>20 µg/min

−10

−5

Harm with Allopurinol

0

5

10

Benefit with Allopurinol

Figure 2. Prespecified Subgroup Analyses of the Effect of Allopurinol on the Primary Outcome.
The mean differences in the primary outcome (the iohexol-based GFR at the end of the 2-month washout period) between the allopuri‑
nol group and the placebo group are shown in prespecified subgroups. Positive values denote a higher iohexol-based GFR in the allopu‑
rinol group than in the placebo group (i.e., benefit with allopurinol); negative values denote a lower iohexol-based GFR in the allopurinol
group than in the placebo group (i.e., harm with allopurinol). Race was reported by the patient.

bling or progression to end-stage kidney disease rinol group than in the placebo group (in 10 paand of fatal or nonfatal cardiovascular events were tients vs. 4). No major imbalances between the
inconclusive owing to small numbers of events. two groups were observed in the distribution of
serious adverse events according to body system
Safety of Allopurinol Treatment
(Table S5).
There were 354 serious adverse events; 171 serious adverse events occurred in the allopurinol
Discussion
group and 183 occurred in the placebo group
(Table S4). The percentages of participants with This randomized clinical trial showed no eviat least one serious adverse event were similar in dence of a clinically meaningful benefit of sethe two groups (93 of 267 patients [34.8%] in the rum urate lowering with allopurinol on kidney
allopurinol group and 82 of 263 [31.2%] in the outcomes in patients with type 1 diabetes and
placebo group), as were the percentages of pa- early-to-moderate diabetic kidney disease who
tients who discontinued allopurinol or placebo were treated, as indicated, with renin–angiotenbecause of such events (16 patients [6.0%] and sin system inhibitors. Despite 3 years of sus11 patients [4.2%], respectively). Although such tained serum urate reduction, there was no evievents were uncommon, there were numerically dence of a difference between the allopurinol
more fatal serious adverse events in the allopu- group and the placebo group in the primary
n engl j med 382;26
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outcome, the baseline-adjusted iohexol-based GFR
after a 2-month washout period. In addition, we
found no evidence of a clinically meaningful
benefit with regard to secondary outcomes, including the iohexol-based GFR at the end of the
intervention period, the iohexol-based and estimated GFR slopes, and serum creatinine doubling or progression to end-stage kidney disease
in a time-to-event analysis. Prespecified subgroup
analyses did not show heterogeneity in the effect
of allopurinol on the primary outcome. Therefore, a reduction in the serum urate level by allo
purinol did not appear to effectively alter the
progression of diabetic kidney disease at early-tomoderate stages in persons with type 1 diabetes.
Several features of the trial make this conclusion robust. First, the rate of kidney-function
decline (mean overall iohexol-based GFR slope
in the placebo group, −2.5 ml per minute per
1.73 m2 per year) was consistent with clinically
significant progression of diabetic kidney disease,31 which confirms the suitability of this
trial population for the study of interventions to
reduce the decline in renal function. Second, this
population provided the trial with more than
80% power to detect a clinically meaningful
treatment effect on GFR (i.e., a decline in GFR
that was 1 ml per minute per 1.73 m2 per year
slower with allopurinol than with placebo,
which is equivalent to an approximately 9-year
postponement of end-stage kidney disease in this
population). Third, adherence to the trial intervention was high, leading to a sustained reduction of 36% in the serum urate level in the allo
purinol group during the intervention period.
Fourth, other factors that potentially influence
GFR decline, such as glycemia, blood pressure,
and renin–angiotensin inhibition, were balanced
between the two groups at baseline and throughout the trial. Fifth, the results for the secondary
outcomes were consistent with those for the primary outcome. In fact, for the urinary albumin
excretion rate, there was the suggestion of a
worse outcome in allopurinol-treated participants
than in those who received placebo. However,
independent validation of this finding in other
cohorts of patients with diabetic kidney disease
is necessary before safety concerns for allopurinol are raised in this regard.
The findings of our trial differ from those of
two smaller trials that had, in part, provided the
impetus for our trial. Siu et al.21 randomly as2500

n engl j med 382;26
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signed 51 patients (24% of whom had diabetes)
to receive allopurinol or placebo for 12 months.
At baseline, the mean serum urate level was
more than 9.5 mg per deciliter (560 μmol per
liter), and the mean serum creatinine level more
than 1.6 mg per deciliter (140 μmol per liter).
They found less decline in kidney function (defined as an increase of ≥40% in the serum creatinine level or end-stage kidney disease) in the
allopurinol group than in the placebo group.
Goicoechea et al.19,20 randomly assigned 113 patients (21% of whom had diabetes; the mean age
of the patients was approximately 20 years older
than in our trial) to receive allopurinol or placebo for 24 months. At the end of this period,
the estimated GFR had increased from baseline
by 1.3 ml per minute per 1.73 m2 in the allopurinol group, whereas it had decreased by 3.3 ml
per minute per 1.73 m2 in the placebo group.
Among these patients overall, the mean estimated GFR at baseline was approximately 40 ml
per minute per 1.73 m2, and the mean serum
urate level was 7.6 mg per deciliter (450 μmol
per liter). Thus, in addition to the participants
being older in their trial than those in ours, the
baseline GFR was lower and the serum urate
level higher in both these earlier trials than in
ours.19-21 Although it is possible that a reduction
in the serum urate level might have been more
effective in slowing the decline in GFR in persons who had more advanced chronic kidney
disease or higher serum urate levels (or both)
than the patients in our cohort, we found no
effect modification by these factors in our secondary analyses. Another recent trial, CKD-FIX
(Controlled Trial of Slowing of Kidney Disease
Progression from the Inhibition of Xanthine
Oxidase),32 did not show a beneficial effect of
allopurinol therapy on the estimated GFR decline
in persons who had a lower estimated GFR at
baseline (mean, 31.7 ml per minute per 1.73 m2)
and a higher serum urate level at baseline (mean,
8.2 mg per deciliter [490 μmol per liter]) than
the patients in our trial.
Our findings might be considered to be inconsistent with observational studies that have
indicated that elevated serum urate levels are
strong and independent predictors of albuminuria and early GFR decline in persons with type 1
and type 2 diabetes.14 Population-based association studies, however, cannot prove causation.
Recent studies with the use of mendelian ran-
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domization methods in large population-based
cohorts, including one with type 1 diabetes,
showed no causal effects of the serum urate
level on the estimated GFR or on the risk of
chronic kidney disease, despite finding positive
associations between the serum urate level and
these outcomes.33,34 One explanation may be that
other traits that are associated with serum urate
levels (e.g., by means of transcriptional co-regulation35) are causally related to diabetic kidney
disease.
Our trial had many strengths, including adequate power, a rigorous protocol, and high participant adherence, which resulted in sustained
reduction in the serum urate level in the allopurinol group. However, some potential limitations
should be acknowledged. If urate promotes kidney damage with long-term exposure, a trial of
longer duration might be necessary to reveal
differences between groups, although the virtually identical primary outcome in the two groups
in this trial makes this unlikely. Treatment with
renin–angiotensin system inhibitors, except if
contraindicated or considered to be unnecessary,
was a trial eligibility criterion. Although a reduction in the serum urate level with allopurinol
therapy may provide benefit in the absence of
these drugs,36 it was not possible to test this
because renin–angiotensin system inhibitors, as
used in this trial, represent the standard of care.12
Although our trial of serum urate reduction
in patients with diabetic kidney disease was large,
data on the primary outcome were missing and
were imputed in approximately 20% of the participants. However, given the results of a sensitivity analysis supporting the robustness of the
imputation process, we think the effect of those
missing data was limited. Also, there were relatively small participant numbers within certain
clinical strata, which limited the power of subgroup analyses to detect heterogeneity in allopurinol effects. Given the preponderance of white
patients in this trial, the results may not be
fully applicable to other races or ethnic groups.
Similarly, the results should not be generalized
to patients with other stages of diabetic kidney
disease; to patients with type 2 diabetes, in
whom increased serum urate may relate to other
processes, such as the metabolic syndrome37; or
to patients with other causes of chronic kidney
disease. However, the similarly neutral results of
CKD-FIX32 make it unlikely that reduction in the
n engl j med 382;26

serum urate level would benefit persons with
these other conditions.
Despite achieving full enrollment and participant completion targets and observing a sustained 36% reduction in the serum urate level
throughout this 3-year trial, we did not find evidence of a clinically meaningful benefit of allopurinol treatment on kidney outcomes among
patients with type 1 diabetes and early-to-moderate diabetic kidney disease who were treated
with renin–angiotensin system inhibitors.
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